

Abstract

5

A tumour vaccine based on tumour antigens contains as active constituent, in addition to a tumour antigen source, a release system with delayed release of active substance for IFN- γ , the effective dose of IFN- γ being
10 50 ng to 5 μ g which is released over a period of from several hours to several days. The release system for IFN- γ preferably consists of liposomes, while the tumour antigen source preferably consists of allogenic tumour cells.

15